xoma corp (XOMA) Snapshot

XOMA Corporation announced it has opened enrollment in a pilot study to determine gevokizumab's potential to treat acute inflammatory pyoderma gangrenosum. Pyoderma gangrenosum (PG) is one of the several rare diseases that are classified under the broader cluster of neutrophilic dermatoses. XOMA's pilot study is designed to enroll up to eight patients who are experiencing acute inflammatory PG. An inflammatory episode of PG is characterized by recently developed active ulcers and ulcer-related pain. XOMA's pilot study is designed to enroll up to eight patients who are experiencing acute inflammatory PG. The study is designed to evaluate the response in the first four patients and be able to make decisions to continue the study with a higher dosing regimen. Patients will be assessed on Day 28 to determine gevokizumab's efficacy in controlling the acute inflammatory symptoms of PG, and on Day 84 to determine gevokizumab's longer-term effect on skin ulcers. Both investigator and patient global assessments will be evaluated throughout the study.

XOMA Corporation reported earnings results for the first quarter of 2013. The company reported total revenues of $9.5 million and $9.9 million in the first quarters of 2013 and 2012, respectively. The small decrease in 2013 revenues reflects a reduction in contract and other revenue associated with NIAID contracts. For the quarter ended March 31, 2013, the company had a net loss of $24.9 million or $0.30 per share, compared with a net loss of $30.4 million or $0.69 per share for the corresponding quarter of 2012. The net loss for the first quarters of 2013 and 2012 included a non-cash charge of $12.8 million or $0.16 per share and $14.4 million or $0.33 per share, respectively. Excluding these non-cash charges, the net loss in the first quarters of 2013 and 2012 were $12 million or $0.15 a share and $16 million or $0.36 per share, respectively.

XOMA Corporation Presents at Credit Suisse 2013 Antibody Day, May-10-2013 08:30 AM. Venue: New York, New York, United States. Speakers: Paul D. Rubin, Chief Medical Officer and Senior Vice President of Clinical Development.